Medical Meetings

Our success as a next-generation BioPharma company will be measured by the difference we can make in the lives of patients facing serious disease. Members of the press may learn more about our company, our philanthropy and our focus on innovative medicines by viewing these resources.

BMS at ASCO and EHA 2022

BMS at Immunology Meetings

At this year's meetings across rheumatology, gastroenterology, dermatology and neurology, we shared data showcasing our commitment to advancing pathbreaking science and innovation for advancing care for people living with immune-mediated diseases. 

BMS at EULAR 2022 >

The European Congress of Rheumatology (EULAR) 2022 represented an important touchpoint for scientific breakthroughs and exchange to address unmet needs for people living with rheumatic diseases.

BMS at DDW 2022 >

Digestive Disease Week (DDW) 2022 represented an important opportunity to showcase the latest research and breakthroughs for people living with gastrointestinal (GI) immune-mediated diseases.

BMS at EADV Congress 2022 >

The European Academy of Dermatology and Venereology (EADV) Congress 2022 serves as an important opportunity to engage in scientific exchange with the dermatology research and medical community.

BMS at 2022 EAN >

The 2022 European Association of Neurology (EAN) annual meeting represented an important opportunity for scientific exchange for the neurology research community to elevate patient care.

BMS at the 63rd ASH Annual Meeting & Exposition >

At the American Society of Hematology (ASH) Annual Meeting 2021, Bristol Myers Squibb shared new data demonstrating the strength of our our innovative therapeutic platforms and modalities in a broad range of hematologic diseases.

BMS at AHA Scientific Sessions 2021 >

At the AHA 2021 Scientific Sessions, Bristol Myers Squibb shared updates from our robust cardiovascular pipeline and highlighted key research programs that propel discovery of treatment options for patients with cardiovascular disease.